Halfway through 2016 – one year into the deepest drawdowns in the history of the biotech sector – a major healthcare and life sciences investment fund wants to explain its performance, rated as one of the best by one study. RA Capital, down -16.4% year to date, says the political rhetoric will subside After starting the year down more than -21%, but since recovering to down -16.4% as of the end of June, RA Capital Healthcare Fund says mean reversion could be upon us. The drawdown – and the political reaction against healthcare in the wake of Martin Shkreli and…
RA Capital Says Better Times Ahead For Healthcare, Biotech As Fund Drops 16% In H1
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.